Chapter 20: Anti-Bacterial Medications: Review

The fluoroquinolone class, represented prominently by ciprofloxacin and related compounds, functions through inhibition of bacterial dna gyrase, preventing proper dna replication and transcription in susceptible organisms. The chapter analyzes the pharmacokinetic properties of fluoroquinolones, their clinical applications across various infection types, and the concerning emergence of bacterial resistance patterns that limit their utility. Adverse effects specific to this drug class and important patient management considerations are thoroughly addressed. A substantial portion focuses on glycopeptide antibiotics, particularly vancomycin and newer agents including telavancin, dalbavancin, and oritavancin, which are essential for treating gram-positive infections resistant to other medications. These agents disrupt bacterial cell wall synthesis by inhibiting peptidoglycan cross-linking, making them invaluable for severe infections. The chapter emphasizes the clinical significance of red man syndrome, a hypersensitivity reaction characterized by histamine release triggered during rapid intravenous administration, and strategies for preventing this complication. Daptomycin, a lipopeptide antibiotic with a unique mechanism targeting bacterial cell membranes rather than cell wall components, is explored for its distinctive properties and clinical role in specific infections. The final section addresses antimetabolite antibiotics, particularly the synergistic combination of trimethoprim and sulfamethoxazole, which work through competitive inhibition of folate synthesis pathways essential for bacterial survival. Sulfonamides competitively block para-aminobenzoic acid utilization, preventing the production of dihydrofolate necessary for nucleotide synthesis. The chapter integrates mechanisms of action, pharmacokinetic characteristics, therapeutic indications, and adverse effect profiles for each drug class to provide comprehensive understanding of these essential antimicrobial agents in clinical practice.